NCT04125693 2022-04-01Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its SafetyBayerPhase 2 Completed1 enrolled
NCT01976741 2021-05-06Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)BayerPhase 1 Completed168 enrolled 59 charts